bluebird bio Statistics
Total Valuation
bluebird bio has a market cap or net worth of $48.77 million. The enterprise value is $187.02 million.
Important Dates
The last earnings date was Wednesday, May 14, 2025, after market close.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
bluebird bio has 9.79 million shares outstanding. The number of shares has increased by 46.73% in one year.
| Current Share Class | 9.79M |
| Shares Outstanding | 9.79M |
| Shares Change (YoY) | +46.73% |
| Shares Change (QoQ) | +0.34% |
| Owned by Insiders (%) | 0.46% |
| Owned by Institutions (%) | 34.80% |
| Float | 9.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.47 |
| Forward PS | 0.20 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.80 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.55
| Current Ratio | 0.55 |
| Quick Ratio | 0.26 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.97 |
Financial Efficiency
Return on equity (ROE) is -546.54% and return on invested capital (ROIC) is -37.22%.
| Return on Equity (ROE) | -546.54% |
| Return on Assets (ROA) | -28.37% |
| Return on Invested Capital (ROIC) | -37.22% |
| Return on Capital Employed (ROCE) | 1,100.96% |
| Revenue Per Employee | $419,137 |
| Profits Per Employee | -$806,371 |
| Employee Count | 248 |
| Asset Turnover | 0.22 |
| Inventory Turnover | 1.33 |
Taxes
In the past 12 months, bluebird bio has paid $170,000 in taxes.
| Income Tax | 170,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -74.23% in the last 52 weeks. The beta is 0.32, so bluebird bio's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | -74.23% |
| 50-Day Moving Average | 4.36 |
| 200-Day Moving Average | 7.74 |
| Relative Strength Index (RSI) | 63.21 |
| Average Volume (20 Days) | 969,228 |
Short Selling Information
The latest short interest is 281,482, so 2.87% of the outstanding shares have been sold short.
| Short Interest | 281,482 |
| Short Previous Month | 428,147 |
| Short % of Shares Out | 2.87% |
| Short % of Float | 2.89% |
| Short Ratio (days to cover) | 1.11 |
Income Statement
In the last 12 months, bluebird bio had revenue of $103.95 million and -$199.98 million in losses. Loss per share was -$20.59.
| Revenue | 103.95M |
| Gross Profit | 28.19M |
| Operating Income | -210.51M |
| Pretax Income | -91.14M |
| Net Income | -199.98M |
| EBITDA | -149.20M |
| EBIT | -210.51M |
| Loss Per Share | -$20.59 |
Full Income StatementBalance Sheet
The company has $78.74 million in cash and $217.00 million in debt, giving a net cash position of -$138.25 million or -$14.12 per share.
| Cash & Cash Equivalents | 78.74M |
| Total Debt | 217.00M |
| Net Cash | -138.25M |
| Net Cash Per Share | -$14.12 |
| Equity (Book Value) | -57.87M |
| Book Value Per Share | -5.91 |
| Working Capital | -140.55M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$228.79 million and capital expenditures -$1.68 million, giving a free cash flow of -$230.47 million.
| Operating Cash Flow | -228.79M |
| Capital Expenditures | -1.68M |
| Free Cash Flow | -230.47M |
| FCF Per Share | -$23.54 |
Full Cash Flow StatementMargins
Gross margin is 27.12%, with operating and profit margins of -202.52% and -192.39%.
| Gross Margin | 27.12% |
| Operating Margin | -202.52% |
| Pretax Margin | -192.22% |
| Profit Margin | -192.39% |
| EBITDA Margin | -143.53% |
| EBIT Margin | -202.52% |
| FCF Margin | n/a |
Dividends & Yields
bluebird bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -46.73% |
| Shareholder Yield | -46.73% |
| Earnings Yield | -410.08% |
| FCF Yield | -472.60% |
Dividend DetailsAnalyst Forecast
The average price target for bluebird bio is $44.60, which is 795.58% higher than the current price. The consensus rating is "Hold".
| Price Target | $44.60 |
| Price Target Difference | 795.58% |
| Analyst Consensus | Hold |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 48.63% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on December 13, 2024. It was a reverse split with a ratio of 0.05:1.
| Last Split Date | Dec 13, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.05:1 |
Scores
bluebird bio has an Altman Z-Score of -23.78 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -23.78 |
| Piotroski F-Score | 2 |